Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
RFS/DFS | 0.40 [0.20, 0.79] | | < 1 | | 0% | 1 study (1/-) | 99.6 % | NA | not evaluable | | important | - |
safety endpoints 00 |
AE leading to death (grade 5) | 1.02 [0.02, 52.25] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
AE leading to treatment discontinuation (any grade) | 11.33 [4.34, 29.62] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
AE leading to treatment discontinuation (grade 3-4) | 11.38 [3.94, 32.84] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
SAE (any grade) | 3.69 [1.68, 8.08] | | < 1 | | 0% | 1 study (1/-) | 0.1 % | NA | not evaluable | | non important | - |
SAE (grade 3-4) | 3.48 [1.58, 7.66] | | < 1 | | 0% | 1 study (1/-) | 0.1 % | NA | not evaluable | | non important | - |
STRAE (any grade) | 5.69 [2.43, 13.31] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
STRAE (grade 3-4) | 4.68 [1.93, 11.38] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
TRAE (any grade) | 5.07 [1.04, 24.68] | | < 1 | | 0% | 1 study (1/-) | 2.2 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) | 6.66 [2.91, 15.27] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
TRAE leading to death (grade 5) | 1.02 [0.02, 52.25] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
TRAE leading to discontinuation (any grade) | 11.33 [4.34, 29.62] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
TRAE leading to discontinuation (grade 3-4) | 11.38 [3.94, 32.84] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
Abdominal pain TRAE (grade 3-4) | 1.02 [0.02, 52.25] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
Acute kidney injury TRAE (grade 3-4) | 2.06 [0.07, 62.55] | | < 1 | | 0% | 1 study (1/-) | 34.2 % | NA | not evaluable | | non important | - |
Adrenal insufficiency TRAE (grade 3-4) | 2.06 [0.07, 62.55] | | < 1 | | 0% | 1 study (1/-) | 34.2 % | NA | not evaluable | | non important | - |
Alopecia TRAE (grade 3-4) | 1.02 [0.02, 52.25] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
Anaemia TRAE (grade 3-4) | 2.06 [0.07, 62.55] | | < 1 | | 0% | 1 study (1/-) | 34.2 % | NA | not evaluable | | non important | - |
Arthralgia TRAE (grade 3-4) | 0.25 [0.01, 5.62] | | < 1 | | 0% | 1 study (1/-) | 80.7 % | NA | not evaluable | | non important | - |
Blood and lymphatic system disorders TRAE (grade 3-4) | 1.02 [0.02, 52.25] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
Chills TRAE (grade 3-4) | 1.02 [0.02, 52.25] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
Colitis TRAE (grade 3-4) | 6.40 [0.31, 130.93] | | < 1 | | 0% | 1 study (1/-) | 11.7 % | NA | not evaluable | | non important | - |
Cough TRAE (grade 3-4) | 1.02 [0.02, 52.25] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
Decreased appetite TRAE (grade 3-4) | 1.02 [0.02, 52.25] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
Diabetes TRAE (grade 3-4) | 0.50 [0.02, 15.35] | | < 1 | | 0% | 1 study (1/-) | 65.1 % | NA | not evaluable | | non important | - |
Diarrhoea TRAE (grade 3-4) | 1.02 [0.06, 16.70] | | < 1 | | 0% | 1 study (1/-) | 49.5 % | NA | not evaluable | | non important | - |
Dizziness TRAE (grade 3-4) | 1.02 [0.02, 52.25] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
Dry skin TRAE (grade 3-4) | 1.02 [0.02, 52.25] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
Dysgeusia TRAE (grade 3-4) | 1.02 [0.02, 52.25] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
Dyspepsia TRAE (grade 3-4) | 1.02 [0.02, 52.25] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
Dyspnoea TRAE (grade 3-4) | 1.02 [0.02, 52.25] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
Ear and labyrinth disorders TRAE (grade 3-4) | 1.02 [0.02, 52.25] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
Endocrine disorders TRAE (grade 3-4) | 5.50 [0.62, 48.70] | | < 1 | | 0% | 1 study (1/-) | 6.4 % | NA | not evaluable | | non important | - |
Eye disorders TRAE (grade 3-4) | 2.06 [0.07, 62.55] | | < 1 | | 0% | 1 study (1/-) | 34.2 % | NA | not evaluable | | non important | - |
Fatigue TRAE (grade 3-4) | 1.02 [0.02, 52.25] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
Gastritis TRAE (grade 3-4) | 4.19 [0.18, 95.03] | | < 1 | | 0% | 1 study (1/-) | 18.7 % | NA | not evaluable | | non important | - |
Gastrointestinal disorders TRAE (grade 3-4) | 9.36 [1.13, 77.61] | | < 1 | | 0% | 1 study (1/-) | 2.0 % | NA | not evaluable | | non important | - |
General disorders and administration site conditions TRAE (grade 3-4) | 4.19 [0.18, 95.03] | | < 1 | | 0% | 1 study (1/-) | 18.7 % | NA | not evaluable | | non important | - |
Headache TRAE (grade 3-4) | 1.02 [0.02, 52.25] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
Hepatitis TRAE (grade 3-4) | 3.31 [0.64, 17.15] | | < 1 | | 0% | 1 study (1/-) | 7.8 % | NA | not evaluable | | non important | - |
Hepatobiliary disorders TRAE (grade 3-4) | 7.53 [1.60, 35.49] | | < 1 | | 0% | 1 study (1/-) | 0.5 % | NA | not evaluable | | non important | - |
Hypertension TRAE (grade 3-4) | 1.02 [0.02, 52.25] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
Hyperthyroidism TRAE (grade 3-4) | 6.40 [0.31, 130.93] | | < 1 | | 0% | 1 study (1/-) | 11.7 % | NA | not evaluable | | non important | - |
Hypophysitis TRAE (grade 3-4) | 0.50 [0.02, 15.35] | | < 1 | | 0% | 1 study (1/-) | 65.1 % | NA | not evaluable | | non important | - |
Hypothyroidism TRAE (grade 3-4) | 1.02 [0.02, 52.25] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
Increase AST TRAE (grade 3-4) | 3.01 [0.75, 12.00] | | < 1 | | 0% | 1 study (1/-) | 6.0 % | NA | not evaluable | | non important | - |
Increased ALT TRAE (grade 3-4) | 5.47 [1.46, 20.45] | | < 1 | | 0% | 1 study (1/-) | 0.6 % | NA | not evaluable | | non important | - |
Increased lipase level TRAE (grade 3-4) | 3.01 [0.75, 12.00] | | < 1 | | 0% | 1 study (1/-) | 6.0 % | NA | not evaluable | | non important | - |
Infusion-related reactions TRAE (grade 3-4) | 1.02 [0.02, 52.25] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
Leucopenia TRAE (grade 3-4) | 1.02 [0.02, 52.25] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
Maculopapular rash TRAE (grade 3-4) | 2.06 [0.07, 62.55] | | < 1 | | 0% | 1 study (1/-) | 34.2 % | NA | not evaluable | | non important | - |
Metabolism and nutrition disorders TRAE (grade 3-4) | 1.02 [0.06, 16.70] | | < 1 | | 0% | 1 study (1/-) | 49.5 % | NA | not evaluable | | non important | - |
Musculoskeletal and connective tissue disorders TRAE (grade 3-4) | 0.16 [0.01, 3.31] | | < 1 | | 0% | 1 study (1/-) | 87.9 % | NA | not evaluable | | non important | - |
Myalgia TRAE (grade 3-4) | 0.50 [0.02, 15.35] | | < 1 | | 0% | 1 study (1/-) | 65.1 % | NA | not evaluable | | non important | - |
Myositis TRAE (grade 3-4) | 1.02 [0.02, 52.25] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
Nausea TRAE (grade 3-4) | 1.02 [0.02, 52.25] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
Nervous system disorders TRAE (grade 3-4) | 0.50 [0.04, 5.68] | | < 1 | | 0% | 1 study (1/-) | 71.0 % | NA | not evaluable | | non important | - |
Neutropenia TRAE (grade 3-4) | 1.02 [0.02, 52.25] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4) | 1.02 [0.02, 52.25] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
Pancreatitis TRAE (grade 3-4) | 1.02 [0.02, 52.25] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
Paraesthesia TRAE (grade 3-4) | 1.02 [0.02, 52.25] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
Peripheral neuropathy TRAE (grade 3-4) | 2.06 [0.07, 62.55] | | < 1 | | 0% | 1 study (1/-) | 34.2 % | NA | not evaluable | | non important | - |
Pneumonitis TRAE (grade 3-4) | 1.02 [0.02, 52.25] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
Pruritus TRAE (grade 3-4) | 1.02 [0.02, 52.25] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
Pyrexia TRAE (grade 3-4) | 4.19 [0.18, 95.03] | | < 1 | | 0% | 1 study (1/-) | 18.7 % | NA | not evaluable | | non important | - |
Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) | 1.02 [0.02, 52.25] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
Sarcoidosis TRAE (grade 3-4) | 1.02 [0.02, 52.25] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
Skin and subcutaneous tissue disorders TRAE (grade 3-4) | 3.17 [0.32, 31.48] | | < 1 | | 0% | 1 study (1/-) | 16.4 % | NA | not evaluable | | non important | - |
Stomatitis TRAE (grade 3-4) | 1.02 [0.02, 52.25] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
Thrombocytopenia TRAE (grade 3-4) | 2.06 [0.07, 62.55] | | < 1 | | 0% | 1 study (1/-) | 34.2 % | NA | not evaluable | | non important | - |
Thyroiditis TRAE (grade 3-4) | 1.02 [0.02, 52.25] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
Uveitis TRAE (grade 3-4) | 1.02 [0.02, 52.25] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
Vitiligo TRAE (grade 3-4) | 1.02 [0.02, 52.25] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
Vomiting TRAE (grade 3-4) | 1.02 [0.02, 52.25] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
Weight decreased TRAE (grade 3-4) | 1.02 [0.02, 52.25] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |